Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MONOCLONAL ANTIBODIES WILL PAY HYBRITECH 15% ROYALTIES

Executive Summary

MONOCLONAL ANTIBODIES WILL PAY HYBRITECH 15% ROYALTIES on its RAMP HCG, Advance pregnancy tests and OvuStick ovulation test until the products are reformulated, Monoclonal Antibodies said July 2. Royalty payments will be made on both domestic and foreign sales, according to Monoclonal Antibodies. The products were found to infringe Hybritech's sandwich assay patent in a suit filed by Hybritech in 1984. Monoclonal Antibodies also agreed to pay Hybritech $2.2 mil. in settlement of all past claims on the patent. The settlement calls for an immediate payment of $1 mil. and subsequent payments of $250,000 beginning Sept. 30. Hybritech granted the company a one-year license to manufacture and sell the infringing products under the royalty arrangement. Monoclonal says it already has made "substantial progress on reformulating our products with polyclonal antibodies so as to avoid infringement of the Hybritech patent claims," Monoclonal President Thomas Glaze commented. Glaze added that the license will allow the company to begin reshipping the products which had been enjoined from sale by a May 21 preliminary injunction.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel